[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"nav-categories":3,"article-from-lab-to-market-how-mabion-helps-biotechs-scale-production-efficiently":70},{"data":4},[5,37,57,64],{"name":6,"slug":7,"categories":8},"Productivity","productivity",[9,13,17,21,25,29,33],{"id":10,"title":11,"slug":12},17,"Branding","branding",{"id":14,"title":15,"slug":16},19,"Marketing","marketing",{"id":18,"title":19,"slug":20},20,"Work","work",{"id":22,"title":23,"slug":24},34,"Community","community",{"id":26,"title":27,"slug":28},21,"For newbies","for-newbies",{"id":30,"title":31,"slug":32},24,"Investment","investment",{"id":34,"title":35,"slug":36},22,"Finance","finance",{"name":38,"slug":39,"categories":40},"Tech","tech",[41,45,49,53],{"id":42,"title":43,"slug":44},28,"Technology","technology",{"id":46,"title":47,"slug":48},32,"Artificial Intelligence","artificial-intelligence",{"id":50,"title":51,"slug":52},26,"Security and protection","security-and-protection",{"id":54,"title":55,"slug":56},31,"YouTube Blog","youtube-blog",{"name":58,"slug":59,"categories":60},"News","news",[61],{"id":62,"title":58,"slug":63},18,"quasanews",{"name":65,"slug":66,"categories":67},"Business","business",[68],{"id":69,"title":65,"slug":66},16,{"post":71,"published_news":94,"popular_news":152,"categories":216},{"title":72,"description":73,"meta_title":72,"meta_description":74,"meta_keywords":75,"text":76,"slug":77,"created_at":78,"publish_at":78,"formatted_created_at":79,"category_id":42,"links":80,"view_type":83,"video_url":84,"views":85,"likes":86,"lang":87,"comments_count":86,"category":88},"From lab to market: How Mabion helps biotechs scale production efficiently","This blog explores how an effective CDMO partnership supports biotech innovators at every step of this\ntransition, combining scientific rigor, digital tools and a flexible mindset to scale production efficiently while\nmaintaining the highest quality standards.","For biotech companies, having the right contract development and manufacturing partner (CDMO) means speeding time to market.","right biologics CDMO partner, Bioprocess, lab-scale cell culture, multimodal chromatography on ÄKTA™ platforms, Beacon Select System for high-throughput cell line development","\u003Cp>For biotech companies, scaling from early discovery to commercial manufacturing is a multi-step process that presents significant challenges. From process development and tech transfer to regulatory planning and large-scale production, each stage introduces its own risks and roadblocks. Having the right contract development and manufacturing (CDMO) partner can make the difference between a streamlined path to market and costly delays. This blog explores how an effective CDMO partnership supports biotech innovators at every step of this transition, combining scientific rigor, digital tools and a flexible mindset to scale production efficiently while maintaining the highest quality standards.\u003C/p>\n\n\u003Chr />\n\u003Ch4>\u003Cstrong>Building continuity and confidence into scale-up\u003C/strong>\u003C/h4>\n\n\u003Chr />\n\u003Cp>One of the most \u003Cstrong>common pain points during scale-up is the disconnect between laboratory-scale development and full GMP manufacturing\u003C/strong>. Different equipment, workflows and teams can cause inconsistencies that delay progress or compromise product integrity. This can be solved with a deliberately aligned infrastructure, using the same types of bioreactors and analytical platforms across our R&D and manufacturing facilities. Applying technical continuity smooths the transition from bench to large-scale production, reducing errors and improving reproducibility.\u003C/p>\n\n\u003Cp>Involving manufacturing and quality control teams early in development is critical. These \u003Cstrong>cross-functional teams work together to identify potential bottlenecks\u003C/strong>, like purification limitations or equipment compatibility, before they become issues. Collaboration between different teams ensures that the process is built with commercial readiness in mind from the start.\u003C/p>\n\n\u003Cp>Another factor that can build continuity and confidence into scale-up is \u003Cstrong>deep scientific engagement with each molecule\u003C/strong>. Rather than treating the process as a one-size-fits-all template, teams should work to understand the structure, behavior and potential risks of the molecule in development. This enables proactive mitigation strategies and helps preserve critical quality attributes as the process scales.\u003C/p>\n\n\u003Chr />\n\u003Ch4>\u003Cstrong>Speed and flexibility through digital and strategic integration\u003C/strong>\u003C/h4>\n\n\u003Chr />\n\u003Cp>For emerging biotechs, speed is a competitive advantage and an integrated, agile approach helps deliver it without compromising quality. Advanced digital tools, proactive regulatory planning and adaptable infrastructure can help ensure scale-up that is both fast and strategic. Effective strategies include:\u003C/p>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>Bioprocess modeling tailored to specific projects or platform processes\u003C/strong>\u003C/li>\n\u003C/ul>\n\n\u003Cp>Bioprocess modeling plays a vital role in accelerating development and ensuring robust scale-up. When tailored to the unique characteristics of a molecule or process platform, bioprocess modeling supports both upstream and downstream design while reducing development cycles and enhancing predictability.\u003C/p>\n\n\u003Cp>Technologies commonly used in this context include ambr® systems for optimizing lab-scale cell culture, multimodal chromatography on ÄKTA™ platforms for efficient protein purification and the Beacon Select System for high-throughput \u003Ca href=\"https://www.mabion.eu/cell-line-development-banking/\">cell line development\u003C/a>. These tools enable more informed decision-making and support seamless transitions from early development through to manufacturing.\u003C/p>\n\n\u003Cp>● \u003Cstrong>Early and continuous regulatory alignment to help prevent downstream bottlenecks\u003C/strong>\u003C/p>\n\n\u003Cp>Involving regulatory affairs teams at the very start of each project ensures that every process is designed with compliance in mind. This early engagement enables tailored validation strategies appropriate to the project’s clinical phase, such as prioritizing only the essential qualification steps for Phase I trials. As a result, costly over-engineering is avoided and projects stay aligned with evolving regulatory expectations, reducing approval risks and keeping timelines intact.\u003C/p>\n\n\u003Cp>● \u003Cstrong>Right-sized manufacturing infrastructure to provide flexibility across development stages\u003C/strong>\u003C/p>\n\n\u003Cp>Not all therapies require large-scale production. A diverse range of bioreactor capacities, from 50 L to 200 L, can be ideal for clinical batches, personalized therapies and targeted biologics. This scalable infrastructure enables biotechs to produce high-quality material at volumes appropriate to each development phase, avoiding unnecessary investment in oversized systems while maintaining agility as product demands evolve.\u003C/p>\n\n\u003Cp>This \u003Cstrong>combination of digital fluency, strategic foresight and infrastructure flexibility, enables biotechs to move quickly\u003C/strong>, pivot confidently and scale efficiently while maintaining regulatory and technical integrity.\u003C/p>\n\n\u003Chr />\n\u003Ch4>\u003Cstrong>Mabion: A true partnership for scaling efficiently\u003C/strong>\u003C/h4>\n\n\u003Chr />\n\u003Cp>At Mabion, our team works as an extension of your team, rather than a service provider. Dedicated project managers serve as primary points of contact, while regular scientific meetings and transparent updates foster true collaboration. This relationship-first mindset helps build long-term partnerships that start small and scale strategically.\u003C/p>\n\n\u003Cp>Scaling biologics from lab to market is a complex process but with the right \u003Ca href=\"https://www.mabion.eu/\">biologics CDMO\u003C/a> partner, it doesn’t have to be a risky one. We bring together scientific depth, operational flexibility and strategic collaboration to help biotechs confidently scale their innovations and bring them to patients faster.\u003C/p>","from-lab-to-market-how-mabion-helps-biotechs-scale-production-efficiently","2025-11-17T16:52:21.000000Z","17.11.2025",{"image":81,"thumb":82},"https://quasa.io/storage/images/news/xLmCzhv3O4RCJaFFMfvFKg83bYxdQy0gPQDspdcu.jpg","https://api.quasa.io/thumbs/news-thumb/images/news/xLmCzhv3O4RCJaFFMfvFKg83bYxdQy0gPQDspdcu.jpg","large",null,649,0,"en",{"id":42,"title":43,"slug":44,"meta_title":89,"meta_description":90,"meta_keywords":91,"deleted_at":84,"created_at":92,"updated_at":93,"lang":87},"Quasa media blog about growth hacking in Tech","All the most interesting and useful about technologies. Exclusive articles from technologies you won't find anywhere else.","Technology, tech, business, ai, gadget, gadgets, life hacks","2023-03-23T08:15:32.000000Z","2024-08-25T15:37:57.000000Z",[95,109,120,131,142],{"title":96,"description":97,"slug":98,"created_at":99,"publish_at":100,"formatted_created_at":101,"category":102,"links":103,"view_type":106,"video_url":84,"views":107,"likes":86,"lang":87,"comments_count":86,"is_pinned":108},"Why a Chatbot Is Not AI Implementation (Even If It “Works”)","In boardrooms around the world, the conversation about “AI transformation” often begins and ends with the same sentence:\n“Let’s launch a chatbot.”","why-a-chatbot-is-not-ai-implementation-even-if-it-works","2026-04-04T11:25:59.000000Z","2026-04-11T09:17:00.000000Z","11.04.2026",{"title":47,"slug":48},{"image":104,"thumb":105},"https://quasa.io/storage/images/news/5nXl751JTSJQGGTReajb8EcjviD8xjHfasr7izYk.jpg","https://api.quasa.io/thumbs/news-thumb/images/news/5nXl751JTSJQGGTReajb8EcjviD8xjHfasr7izYk.jpg","small",90,false,{"title":110,"description":111,"slug":112,"created_at":113,"publish_at":114,"formatted_created_at":101,"category":115,"links":116,"view_type":106,"video_url":84,"views":119,"likes":86,"lang":87,"comments_count":86,"is_pinned":108},"Chatbots and the Already-Gone","Danish scientists teamed up with shrinks and did what any sane person would do in 2026: they dug into whether AI is making the already-batshit even more batshit.","chatbots-and-the-already-gone","2026-03-28T20:04:23.000000Z","2026-04-11T06:04:00.000000Z",{"title":47,"slug":48},{"image":117,"thumb":118},"https://quasa.io/storage/images/news/2BZyVo3V4JYjSwSr0Sx8nPKR0kpXPIprTvE0pNTt.jpg","https://api.quasa.io/thumbs/news-thumb/images/news/2BZyVo3V4JYjSwSr0Sx8nPKR0kpXPIprTvE0pNTt.jpg",186,{"title":121,"description":122,"slug":123,"created_at":124,"publish_at":125,"formatted_created_at":101,"category":126,"links":127,"view_type":106,"video_url":84,"views":130,"likes":86,"lang":87,"comments_count":86,"is_pinned":108},"Market Sizing in Minutes: How Claude AI Just Turned TAM, SAM, and SOM Analysis into a 2-Minute Superpower","For years, calculating Total Addressable Market (TAM), Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM) was one of the most tedious parts of any strategy, pitch deck, or go-to-market plan.","market-sizing-in-minutes-how-claude-ai-just-turned-tam-sam-and-som-analysis-into-a-2-minute-superpower","2026-03-28T18:02:11.000000Z","2026-04-11T03:52:00.000000Z",{"title":19,"slug":20},{"image":128,"thumb":129},"https://quasa.io/storage/images/news/WqSZ1w4RUZJdakkDj5L1v09G7bkmNxCVAU244BAb.jpg","https://api.quasa.io/thumbs/news-thumb/images/news/WqSZ1w4RUZJdakkDj5L1v09G7bkmNxCVAU244BAb.jpg",274,{"title":132,"description":133,"slug":134,"created_at":135,"publish_at":135,"formatted_created_at":136,"category":137,"links":138,"view_type":106,"video_url":84,"views":141,"likes":86,"lang":87,"comments_count":86,"is_pinned":108},"Marble 1.1 — World Labs Just Made Their World Model Significantly Better","World Labs has released a meaningful update to its generative world model: Marble 1.1 and a new, more powerful variant called Marble 1.1 Plus.","marble-1-1-world-labs-just-made-their-world-model-significantly-better","2026-04-10T19:22:07.000000Z","10.04.2026",{"title":43,"slug":44},{"image":139,"thumb":140},"https://quasa.io/storage/images/news/Klmcbo6URuD0uYTxZn4aR9x8zl98NpFfsdMHTGHw.jpg","https://api.quasa.io/thumbs/news-thumb/images/news/Klmcbo6URuD0uYTxZn4aR9x8zl98NpFfsdMHTGHw.jpg",610,{"title":143,"description":144,"slug":145,"created_at":146,"publish_at":146,"formatted_created_at":136,"category":147,"links":148,"view_type":106,"video_url":84,"views":151,"likes":86,"lang":87,"comments_count":86,"is_pinned":108},"Unmasking Runway Characters: The Unexpected Rise of the Real-Time Avatar","The generative AI landscape is moving so fast it's sometimes hard to keep up. But just when we thought we knew what to expect from major players like Runway, they dropped a curveball: Runway Characters.","unmasking-runway-characters-the-unexpected-rise-of-the-real-time-avatar","2026-04-10T19:04:45.000000Z",{"title":58,"slug":63},{"image":149,"thumb":150},"https://quasa.io/storage/images/news/Lxi7mPfuvku81DkTvlELBfErpx8nbus6cXvBCWMk.jpg","https://api.quasa.io/thumbs/news-thumb/images/news/Lxi7mPfuvku81DkTvlELBfErpx8nbus6cXvBCWMk.jpg",554,[153,166,179,191,204],{"title":154,"description":155,"slug":156,"created_at":157,"publish_at":158,"formatted_created_at":159,"category":160,"links":161,"view_type":106,"video_url":84,"views":164,"likes":165,"lang":87,"comments_count":86,"is_pinned":108},"The Anatomy of an Entrepreneur","Entrepreneur is a French word that means an enterpriser. Enterprisers are people who undertake a business or enterprise with the chance of earning profits or suffering from loss.","the-anatomy-of-an-entrepreneur","2021-08-04T15:18:21.000000Z","2025-12-14T06:09:00.000000Z","14.12.2025",{"title":65,"slug":66},{"image":162,"thumb":163},"https://quasa.io/storage/images/news/mVsXPTMuHZuI7UXCsENgL1Qwp1uSOf7Rz3uVPMfm.webp","https://api.quasa.io/thumbs/news-thumb/images/news/mVsXPTMuHZuI7UXCsENgL1Qwp1uSOf7Rz3uVPMfm.webp",69592,2,{"title":167,"description":168,"slug":169,"created_at":170,"publish_at":171,"formatted_created_at":172,"category":173,"links":174,"view_type":83,"video_url":84,"views":177,"likes":178,"lang":87,"comments_count":86,"is_pinned":108},"Advertising on QUASA","QUASA MEDIA is read by more than 400 thousand people a month. We offer to place your article, add a link or order the writing of an article for publication.","advertising-on-quasa","2022-07-06T07:33:02.000000Z","2025-12-15T17:33:02.000000Z","15.12.2025",{"title":58,"slug":63},{"image":175,"thumb":176},"https://quasa.io/storage/images/news/45SvmdsTQbiyc3nxgbyHY1mpVbisYyub2BCHjqBL.jpg","https://api.quasa.io/thumbs/news-thumb/images/news/45SvmdsTQbiyc3nxgbyHY1mpVbisYyub2BCHjqBL.jpg",69296,4,{"title":180,"description":181,"slug":182,"created_at":183,"publish_at":184,"formatted_created_at":185,"category":186,"links":187,"view_type":106,"video_url":84,"views":190,"likes":178,"lang":87,"comments_count":86,"is_pinned":108},"What is a Startup?","A startup is not a new company, not a tech company, nor a new tech company. You can be a new tech company, if your goal is not to grow high and fast; then, you are not a startup. ","what-is-a-startup","2021-08-04T12:05:17.000000Z","2025-12-17T13:02:00.000000Z","17.12.2025",{"title":65,"slug":66},{"image":188,"thumb":189},"https://quasa.io/storage/images/news/EOsQhSW3VXyG7a6NPdE1oZd00xfJXe3bjY5aJGb7.webp","https://api.quasa.io/thumbs/news-thumb/images/news/EOsQhSW3VXyG7a6NPdE1oZd00xfJXe3bjY5aJGb7.webp",67034,{"title":192,"description":193,"slug":194,"created_at":195,"publish_at":196,"formatted_created_at":197,"category":198,"links":199,"view_type":106,"video_url":84,"views":202,"likes":165,"lang":87,"comments_count":203,"is_pinned":108},"Top 5 Tips to Make More Money as a Content Creator","Content creators are one of the most desired job titles right now. Who wouldn’t want to earn a living online?","top-5-tips-to-make-more-money-as-a-content-creator","2022-01-17T17:31:51.000000Z","2026-01-17T11:30:00.000000Z","17.01.2026",{"title":19,"slug":20},{"image":200,"thumb":201},"https://quasa.io/storage/images/news/gP8kiumBPpJmQv6SMieXiX1tDetx43VwFfO1P4Ca.jpg","https://api.quasa.io/thumbs/news-thumb/images/news/gP8kiumBPpJmQv6SMieXiX1tDetx43VwFfO1P4Ca.jpg",41149,1,{"title":205,"description":206,"slug":207,"created_at":208,"publish_at":209,"formatted_created_at":210,"category":211,"links":212,"view_type":83,"video_url":84,"views":215,"likes":165,"lang":87,"comments_count":86,"is_pinned":108},"8 Logo Design Tips for Small Businesses","Your logo tells the story of your business and the values you stand for.","8-logo-design-tips-for-small-businesses","2021-12-04T21:59:52.000000Z","2025-05-05T03:30:00.000000Z","05.05.2025",{"title":15,"slug":16},{"image":213,"thumb":214},"https://quasa.io/storage/images/news/Wbx2NtS1CnTupgoQbpFMGspJ5jm4uob2hDOq33r0.jpg","https://api.quasa.io/thumbs/news-thumb/images/news/Wbx2NtS1CnTupgoQbpFMGspJ5jm4uob2hDOq33r0.jpg",40328,[217,218,219,220,221,222,223,224,225,226,227,228,229],{"title":23,"slug":24},{"title":47,"slug":48},{"title":55,"slug":56},{"title":43,"slug":44},{"title":51,"slug":52},{"title":31,"slug":32},{"title":35,"slug":36},{"title":27,"slug":28},{"title":19,"slug":20},{"title":15,"slug":16},{"title":58,"slug":63},{"title":11,"slug":12},{"title":65,"slug":66}]